Andrew Keith

Special Counsel
Full contact info

Experience

Innate Pharma - $79 Million IPO

October 24, 2019

Cooley advised Innate Pharma S.A. on its $79.1 million global offering of 14,375,000 ordinary shares, including the full exercise of the underwriters’ option to purchase additional shares. Innate, whose securities now trade on Euronext Paris and Nasdaq Global Select Market under the symbol “IPH," is a French biotechnology company focused on discovering, developing and commercializing first-in-class therapeutic antibodies designed to harness the immune system for the treatment of oncology indications with significant unmet medical need. Partners Richard Segal, Yvan-Claude Pierre and Divakar Gupta led the Cooley team.

Related contacts

Richard Segal
Partner, New York
Yvan-Claude Pierre
Partner, New York
Div Gupta
Partner, New York
Brandon W. Fenn
Partner, New York
Katie Kazem
Partner, Reston
David Dalton
Associate, Santa Monica
Aaron Pomeroy
Partner, Colorado
Darren DeStefano
Partner, Reston
Geoffrey Spolyar
Partner, Boston
Natasha Leskovsek
Of Counsel, Washington, DC
Phil Mitchell
Partner, New York
Andrew Keith
Special Counsel, Washington, DC
Daniel I. Goldberg
Partner, New York

Related Practices & Industries

Global cross-license achieved for Gevo in long-running biofuels patent case

August 27, 2015

Few patent cases make it all the way to the Supreme Court. Even fewer involve a dispute in which a company's very survival is at stake. Since 2011, our client Gevo, a pioneer in the biofuels industry, and Butamax, a joint venture of giants BP and DuPont, had been trading blows, filing close to a dozen patent suits against each other. Butamax initially brought suit in the District of Delaware in an attempt to knock Gevo out of the emerging market for isobutanol alternative energy. In that case, the court granted summary judgment of noninfringement in favor of Gevo, prompting Butamax to appeal. On appeal, the Federal Circuit rejected the district court's claim construction and issued a new claim construction that vacated the noninfringement ruling.

In response, Cooley took the case to the US Supreme Court and, in January 2015, the high court granted our petition for writ of certiorari, vacating the judgment against Gevo and remanding the case back to the Federal Circuit for further consideration. This decision, and numerous other victories including key summary judgment victories, paved the path for Gevo to reach a favorable global patent cross-license and settlement agreement with Butamax. The agreement forms a partnership between the two biofuel companies aimed at leveraging one another's technology.

Related contacts

Dr. Michelle Rhyu
Partner, Palo Alto
Stephen Neal
Chairman Emeritus, Palo Alto
Bonnie Weiss McLeod
Of Counsel, Washington, DC
Daniel Knauss
Partner, Palo Alto
Adam Pivovar
Partner, Washington, DC
Andrew Keith
Special Counsel, Washington, DC

Related Practices & Industries

AcelRx Pharmaceuticals in Public Offering

July 25, 2013

Palo Alto, Calif. – Cooley represented AcelRx Pharmaceuticals. in its public offering of approximately 4.8 million shares of common stock. AcelRx is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain.

The offering closed on July 23, 2013.

Cooley represented AcelRx in its initial public offering in February 2011.

Related contacts

Mark Weeks
Partner, Palo Alto
Chadwick Mills
Partner, San Francisco
Marina Remennik
Special Counsel, Palo Alto
Natasha Leskovsek
Of Counsel, Washington, DC
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Scott Talbot
Partner, Reston
Andrew Keith
Special Counsel, Washington, DC

Pretrial Win for Gevo in Patent Suit

March 27, 2013

Palo Alto, Calif. – Cooley achieved a major victory when it secured a judgment of no infringement on behalf of leading renewable chemicals and advanced biofuels client Gevo in a patent suit brought by Butamax Advanced Biofuels, a joint venture between BP and DuPont.

On March 19, 2013, a Delaware federal judge issued a favorable claim construction ruling for Gevo, granting Gevo partial summary judgment of no infringement under the doctrine of equivalents, and ruling that two key claims of the Butamax patents were invalid. Although the Court did not grant summary judgment of no literal infringement, Butamax acknowledged that it could not prove literal infringement under the court's claim construction and agreed to stipulate to a judgment of no literal infringement.

In January 2011, Butamax filed a patent infringement suit against Gevo asserting two patents relating to the production of isobutanol, a four-carbon alcohol, in microorganisms. Gevo produces its isobutanol using proprietary recombinant yeast that is genetically engineered to produce it at a high yield. In June 2012, the court denied Butamax's request for a preliminary injunction against Gevo, a decision that was upheld by the US Court of Appeals for the Federal Circuit in December 2012. A trial date was set for early April 2013.

"This judgment marks yet another great step forward for Gevo," said Jim Brogan, partner and chair of the intellectual property group."The ruling enables this highly innovative company to continue to focus on its growth and the development of innovative biofuels products."

A separate patent re-examination team has obtained rejections of all challenged claims of the two asserted Butamax patents from the US Patent and Trademark Office.

Related contacts

Matthew Brigham
Of Counsel, Palo Alto
Andrew Keith
Special Counsel, Washington, DC
Daniel Knauss
Partner, Palo Alto
Bonnie Weiss McLeod
Of Counsel, Washington, DC
Stephen Neal
Chairman Emeritus, Palo Alto
Adam Pivovar
Partner, Washington, DC
Dr. Michelle Rhyu
Partner, Palo Alto

Admissions and credentials

District of Columbia

Registered to practice before the United States Patent and Trademark Office (USPTO)

Texas

Virginia